Gilead to provide Sovaldi in India for about $900
Gilead Sciences Inc. (NASDAQ:GILD) said it expects to provide HCV drug Sovaldi sofosbuvir in India at about $300 for a four-week supply -- or $900 for a 12-week course of therapy, which the company said is its standard low-income public pricing structure for Sovaldi. An Indian regulatory submission for Sovaldi is contingent on the completion of an ongoing trial in the country; data from the trial are expected by the end of 2015. According to the World Health Organization, about 12 million people in India have HCV. India has a population of about 1.2 billion.
In March, Gilead said it would provide Sovaldi at the $900 price in Egypt, which the company said has the highest prevalence rate of HCV in the world. In the U.S., the wholesale acquisition cost (WAC) for a 12-week course of Sovaldi is $84,000 (see BioCentury Extra, March 21). ...